Primary Objective~Primary Safety:~To compare safety of oral Ciprodiazole ® tablets (Ciprofloxacin/Metronidazole) versus currently used Ciprofloxacin Tablets & Metronidazole tablets for pelvi-abdominal infections, either non-operative or post-operative following IV antibiotics.~Primary Efficacy:~To compare efficacy of oral Ciprodiazole ® tablets (Ciprofolxacin/Metronidazole) versus currently used Ciprofloxacin Tablets & Metronidazole tablets for pelvi-abdominal infections, either non-operative or post-operative following IV antibiotics.~Secondary Objective~Secondary Safety:~Presence of any signs/symptoms of post-operative wound infection such as redness, fever or wound discharge.~Presence of undesirable effects on total leukocyte count and liver enzymes (SGOT& SGPT)~Secondary Efficacy:~To compare the complete resolution or improvement of Pelvi-abdominal infection between ciprodiazole® versus combined treatment, based on pelvi-abdominal ultrasound and others~To compare the days for complete healing of post-operative wounds between ciprodiazole® versus combined treatment~STUDY DURATION:~Subjects will be enrolled for 12 months including screening visit~Follow up for 15 days from enrolment~STUDY POPULATION:~312 Egyptian Patients with pelvi-abdominal infection or started IV antibiotics in post-operative period, for pelvi - abdominal surgeries and/or acute conditions~ASSESSMENT SCHEDULE:~Subjects will be enrolled for 12 months including screening visit~Visit 1: Screening and treatment initiation visit, Day 0~Follow-up 1 visit: Day 8 (+/-) 3 days~Follow-up 2 visit & End of study visit: Day 15 (+/-) 3 days
This study aims to assess the safety & efficacy of Oral Ciprodiazole® versus currently used Ciprofloxacin Tablets & Metronidazole tablets in pelvi-abdominal infections and following IV antibiotics in post-operative period, for pelvi-abdominal surgeries or acute conditions